Pharming Group
PHAR
Company Profile
Business description
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Contact
Darwinweg 24
LeidenZH2333 CR
NLDT: +31 715247400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
404
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,293.20 | 45.10 | -0.48% |
| CAC 40 | 8,184.96 | 3.63 | -0.04% |
| DAX 40 | 23,910.01 | 362.18 | -1.49% |
| Dow JONES (US) | 45,952.24 | 301.07 | -0.65% |
| FTSE 100 | 9,341.05 | 95.04 | -1.01% |
| HKSE | 25,247.10 | 641.41 | -2.48% |
| NASDAQ | 22,562.54 | 107.54 | -0.47% |
| Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
| NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
| S&P 500 | 6,629.07 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
| SSE Composite Index | 3,839.76 | 76.47 | -1.95% |